Quantinno Capital Management LP Has $2.83 Million Position in Sotera Health Company $SHC

Quantinno Capital Management LP lessened its holdings in Sotera Health Company (NASDAQ:SHC) by 85.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 197,372 shares of the company’s stock after selling 1,204,481 shares during the period. Quantinno Capital Management LP owned approximately 0.07% of Sotera Health worth $2,830,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SHC. CenterBook Partners LP raised its holdings in shares of Sotera Health by 94.1% in the 4th quarter. CenterBook Partners LP now owns 151,529 shares of the company’s stock worth $2,673,000 after buying an additional 73,473 shares in the last quarter. Militia Capital Management LLC acquired a new stake in Sotera Health in the 1st quarter valued at $3,877,000. Geode Capital Management LLC grew its position in Sotera Health by 13.8% in the fourth quarter. Geode Capital Management LLC now owns 3,931,834 shares of the company’s stock valued at $69,372,000 after acquiring an additional 476,365 shares during the period. Balefire LLC acquired a new position in Sotera Health during the first quarter worth $1,476,000. Finally, Sachem Head Capital Management LP raised its stake in Sotera Health by 47.2% during the fourth quarter. Sachem Head Capital Management LP now owns 11,645,000 shares of the company’s stock worth $205,418,000 after acquiring an additional 3,735,000 shares in the last quarter. Institutional investors own 91.03% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on SHC shares. UBS Group set a $19.00 target price on shares of Sotera Health in a research note on Wednesday, June 24th. Citigroup lifted their price target on shares of Sotera Health from $23.00 to $25.00 and gave the company a “buy” rating in a report on Friday. JPMorgan Chase & Co. upped their price objective on shares of Sotera Health from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Friday. Barclays raised their price objective on shares of Sotera Health from $19.00 to $22.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $25.00 target price (up from $22.00) on shares of Sotera Health in a research note on Friday. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.50.

Sotera Health Stock Performance

Sotera Health stock opened at $18.86 on Monday. The stock has a 50-day simple moving average of $17.13 and a 200 day simple moving average of $16.31. The company has a quick ratio of 2.55, a current ratio of 2.80 and a debt-to-equity ratio of 3.33. Sotera Health Company has a 12-month low of $12.94 and a 12-month high of $19.85. The stock has a market capitalization of $5.38 billion, a price-to-earnings ratio of 33.09 and a beta of 1.77.

Sotera Health (NASDAQ:SHC) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. Sotera Health had a net margin of 13.44% and a return on equity of 40.12%. The firm had revenue of $321.38 million for the quarter, compared to analyst estimates of $309.70 million. During the same quarter in the prior year, the firm earned $0.20 EPS. The company’s revenue was up 9.2% on a year-over-year basis. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. On average, research analysts anticipate that Sotera Health Company will post 0.87 earnings per share for the current fiscal year.

More Sotera Health News

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Strong Q2 results and raised outlook: Sotera Health reported adjusted EPS of $0.26, above the $0.24 consensus, while revenue increased 9.2% year over year to $321.4 million, exceeding estimates of $309.7 million. Adjusted EBITDA rose 10%, and net income increased to $53.6 million from $8.0 million a year earlier. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Management raised full-year 2026 guidance: The company increased its constant-currency revenue growth outlook to 5.25%-6.75%, adjusted EBITDA growth outlook to 5.75%-7.25%, and adjusted EPS guidance to $0.95-$1.01. It also expects lower interest expense following a term-loan repricing that should save approximately $3.5 million annually. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Piper Sandler became more bullish: The firm reaffirmed its “overweight” rating and raised its price target from $22 to $25, implying substantial upside from the recent trading level. Benzinga analyst update
• Neutral Sentiment: JPMorgan’s target increase was less constructive: JPMorgan lifted its target from $16 to $18 but maintained a “neutral” rating, leaving its target below the current share price. This may be limiting enthusiasm following the earnings-driven rally. Benzinga analyst update
• Negative Sentiment: Leverage and ongoing risks remain: SHC still carries approximately $2.2 billion of debt, while litigation related to ethylene oxide facilities, inflationary costs and regulatory risks remain potential overhangs. The stock’s valuation also appears demanding relative to JPMorgan’s neutral view.

Insider Buying and Selling at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $15.17, for a total value of $193,194,516.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 15.36% of the stock is currently owned by corporate insiders.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.